In this video update, COO and President, Matthew Mills discusses a new partnership with Eurasian Capital, LLC., shipping to Southeast Asian countries, and year-to-date revenue updates.
Progress on the planning of the IPO continues to move forward. We have officially engaged with Eurasian Capital, LLC. Eurasian Capital has a proven track record of handpicking specific high growth companies and supporting their expansion plans by investing and marketing to their network of pension funds, family offices, hedge funds, private equity firms, venture funds, securities analysts (buy-side/sell-side), stockbrokers, and institutional investors.
As Matthew discussed in the video, we are hoping to be able to make another engagement announcement in the coming weeks in regards to a possible partner who is potentially interested in supporting our efforts with an infusion of large-scale capital to possibly help close the current funding rounds and accelerate the plan to an Initial Public Offering.
We are excited to have such an experienced partner in Eurasian Capital to support the management team on many fronts as well as widely expand our marketing reach. This is another major milestone in the planning process of our IPO. As we continue to build out our team we will continue to update you on planning developments and milestones.
Several institutions have shown strong interest and it is critical that we do our due diligence and select the right partners, with the right experience and track record to move our plan forward in the best interest for the Company and its shareholders.
International distribution continues to grow after the release of the Nature-Cide toxicity reports. Singapore, Thailand, and Vietnam Rentokil Initial are expected to begin shipping soon. Nature-Cide negotiations have accelerated within Australia and Mexico, and will hopefully be our next international positioning.
2020 has turned out to be our best year in the Company's history for digital direct to consumer sales. The ecommerce initiatives we announced in late 2019 have proved successful and we are hopeful the end of the year will be our best Q4 yet. Historically Q4 is our best ecommerce quarter with our Thermal-Aid product lines. This season we were able to bolster our inventory thanks to all of our shareholders' support from earlier in the year and now it is time to reap the benefits going into the holiday season.
Overall in 2020, we have nearly matched our total 2019 revenue numbers here in the 3rd quarter, even before we reach our historically best sales quarter. Management is hopeful that our 2020 revenue will exceed our expectations. Even during Covid-19 we were able to keep the doors open and grow our business. We are all very proud of that, and very grateful to our investors who helped keep the business moving forward.
With our plan continuing to move forward with an IPO, our focus on growth has never been more important. Our plan cannot happen without the continued support of our shareholders and the team to continue to grow the Company. None of this could or can be possible without the hard work of our team and our shareholders pushing the growth. This is a major talking point when Matthew and the management team are in discussions with institutional investors. Doing an IPO is one thing but supporting the share price with continued growth once we go public is critical, and it remains vital that we continue to fund our growth, before and during the process of entering the public market, so we look attractive to larger institutional players once we begin trading to super size our growth potential.
We are very thankful and appreciative to all of our shareholders. If you are closely watching Med-X but have not become an investor yet, we ask you to jump on board and invest. If you are one of the over 3,000 shareholders that has already invested, your continued support is greatly appreciated. If you have questions please contact your investor relations representative and or the management team.
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.